New Proteasome Inhibitors

被引：0

作者：

Orlowski, Robert Z. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA & MYELOMA | 2009年 / 9卷

关键词：

PEGYLATED LIPOSOMAL DOXORUBICIN; MULTIPLE-MYELOMA CELLS; HEMATOLOGIC MALIGNANCIES; BORTEZOMIB; APOPTOSIS; THERAPY; PS-341; TRIAL;

D O I：

10.1016/S1557-9190(11)70827-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S43 / S44

页数：2

共 11 条

[1] A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
Chauhan, D
Catley, L
Li, GL
Podar, K
Hideshima, T
Velankar, M
Mitsiades, C
Mitsiades, N
Yasui, H
Letai, A
Ovaa, H
Berkers, C
Nicholson, B
Chao, TH
Neuteboom, STC
Richardson, P
Palladino, MA
Anderson, KC
[J]. CANCER CELL, 2005, 8 (05) : 407 - 419
[2] Hideshima T, 2001, CANCER RES, V61, P3071
[3] Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Kuhn, Deborah J.
Chen, Qing
Voorhees, Peter M.
Strader, John S.
Shenk, Kevin D.
Sun, Congcong M.
Derno, Susan D.
Bennett, Mark K.
Van Leeuwen, Fijs W. B.
Chanan-Khan, Asher A.
Orlowski, Robert Z.
[J]. BLOOD, 2007, 110 (09) : 3281 - 3290
[4] Proteasome inhibitors in cancer therapy: Lessons from the first decade
Orlowski, Robert Z.
Kuhn, Deborah J.
[J]. CLINICAL CANCER RESEARCH, 2008, 14 (06) : 1649 - 1657
[5] Orlowski RZ, 2007, J CLIN ONCOL, V25, P3892, DOI 10.1200/JCO.2006.10.5460
[6] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
Orlowski, RZ
Stinchcombe, TE
Mitchell, BS
Shea, TC
Baldwin, AS
Stahl, S
Adams, J
Esseltine, DL
Elliott, PJ
Pien, CS
Guerciolini, R
Anderson, JK
Depcik-Smith, ND
Bhagat, R
Lehman, MJ
Novick, SC
O'Connor, OA
Soignet, SL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4420 - 4427
[7] Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
Orlowski, RZ
Voorhees, PM
Garcia, RA
Hall, MD
Kudrik, FJ
Allred, T
Johri, AR
Jones, PE
Ivanova, A
Van Deventer, HW
Gabriel, DA
Shea, TC
Mitchell, BS
Adams, J
Esseltine, DL
Trehu, EG
Green, M
Lehman, MJ
Natoli, S
Collins, JM
Lindley, CM
Dees, EC
[J]. BLOOD, 2005, 105 (08) : 3058 - 3065
[8] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Richardson, PG
Sonneveld, P
Schuster, MW
Irwin, D
Stadtmauer, EA
Facon, T
Harousseau, JL
Ben-Yehuda, D
Lonial, S
Goldschmidt, H
Reece, D
San-Miguel, JF
Bladé, J
Boccadoro, M
Cavenagh, J
Dalton, WS
Boral, AL
Esseltine, DL
Porter, JB
Schenkein, D
Anderson, KC
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) : 2487 - 2498
[9] A phase 2 study of bortezomib in relapsed, refractory myeloma
Richardson, PG
Barlogie, B
Berenson, J
Singhal, S
Jagannath, S
Irwin, D
Rajkumar, SV
Srkalovic, G
Alsina, M
Alexanian, R
Siegel, D
Orlowski, RZ
Kuter, D
Limentani, SA
Lee, S
Hideshima, T
Esseltine, DL
Kauffman, M
Adams, J
Schenkein, DP
Anderson, KC
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) : 2609 - 2617
[10] Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
San Miguel, Jesus F.
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin
Spicka, Ivan
Petrucci, Maria T.
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C.
Esseltine, Dixie L.
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Richardson, Paul G.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09) : 906 - 917

← 1 2 →